Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Established Markets Growth: 2.0% in Q3 2026, down 8.0 pts from a year earlier.
Latest, Q3 2026
2.0%
Period ended Sep 30, 2026
Change on a year earlier
-8.0 pts
10.0% in Q3 2025
History
26 quarters
Since Q2 2020
Sources
26
Documents cited below
Where the Q3 2026 figure comes from
“|| Of which in established markets | 10 739 | 10 489 | 2 | 3 | 74 | 75”
Source: Novartis Form 6-K (0001114448-26-000014) ↗
Reported in Form 6-K.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Novartis Established Markets Growth (%), quarterly Q2 2020–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/geo-established-yoy-usd-pct
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.